Blockers of platelet glycoprotein IIb/IIIa-receptors in the treatment of acute coronary syndrome and in transcutaneous coronary interventions


Cite item

Full Text

References

  1. Цzmen F., Atalar E., Цzer N. Thrombocytes and glycoprotein IIb/IIIa inhibitors in acute coronary syndrome. Turk. J. Cardiol. 2007; 10: 91-100.
  2. Boersma E., Harrington R. A., Moliterno D. J. et al. Platelet glycoprotein llb/llla inhibitors in acute coronary syndromes: a meta-analysis of all major randomised trials. Lancet 2002; 359: 189-198.
  3. Chew D. P., Moliterno D. J. A critical appraisal of platelet glycoprotein IIb/IIIa inhibition. J. Am. Coll. Cardiol. 2000; 36: 2028-2035.
  4. Becker R. C., Fintel D. J., Green D. Antithrombotic therapy. 4-th ed. New York; 2006.
  5. Shimbo D., Pickering Th. Platelet in cardiovascular and noncardiovascular disorders: pathophysiology, pharmacology, and therapeutics. Cardiovasc. Rev. Rep. 2004; 25: 18-24.
  6. Bhatt D. L., Topol E. J. Scientific and therapeutic advances in antiplatelet therapy. Nat. Rev. 2003; 2: 15-28.
  7. Messmore H. L., Jr., Wehrmacher W. H., Cayne E., Jeske W. The clinical utility of antiplatelet drugs revised. Cardiovasc. Rev. Rep. 2004; 25: 29-32.
  8. Topol E. J., Byzova T. V., Plow E. F. Platelet GP IIb/IIIa blockers. Lancet 1999; 353: 227-231.
  9. White H. Unstable angina: Ischemic syndromes. Topol E., (ed) Textbook of cardiovascular medicine. 3-rd ed. Philadelphia; 2007. 251-279.
  10. The GUSTO-IV ACS investigators. Effect of glycoprotein IIb/IIIa receptor blocker abciximab on outcome in patients with acute coronary syndromes without early coronary revascularization: the GUSTO-IV ACS. Lancet 2001; 357: 1915-1924.
  11. The GUSTO-V Investigators. Reperfusion therapy for acute myocardial infarction with fibrinolytic therapy or combination reduced fibrinolytic therapy and platelet glycoprotein IIb/IIIa inhibition: the GUSTO V randomized trial. Lancet 2001 ;357: 1905-1914.
  12. Cook J. J., Bednar B., Lynch J. J. et al. Tirofiban (Aggrastat). Cardiovasc. Drug Rev. 1999; 17: 199-224.
  13. The RESTORE investigators. Effects of platelet glycoprotein IIb/IIIa blockade with tirofiban on adverse cardiac events in unstable angina or myocardial infarction undergoing coronary angioplasty. Circulation 1997; 96: 1445-1453.
  14. The RESTORE investigators. Six month angiographic and clinical follow-up of patients prospectively randomized to either tirofiban or placebo during in the RESTORE. J. Am. Coll. Cardiol. 1998; 32: 28-34.
  15. Valgimigli M., Percoco G., Barbieri D. et al. The additive value of tirofiban administrated with high-dose bolus in the prevention of ischemic complications during high-risk coronary angioplasty. J. Am. Coll. Cardiol. 2004; 44: 14-19.
  16. The Platelet Receptor Inhibition in Ischemic Syndrome Management (PRISM) study investigators. A comparison of aspirin plus tirofiban with aspirin plus heparin for unstable angina. Engl. J. Med. 1998; 338: 1498-1505.
  17. The Platelet Receptor Inhibition in Ischemic Syndrome Management in Patients Limited by Unstable Signs and symptoms (PRISM-PLUS) study investigators. Inhibition of the platelet glycoprotein IIb/IIIa receptor with tirofiban in unstable angina and non-Q-wave myocardial infarction. N. Engl. J. Med. 1998; 338: 1488-1497.
  18. Morrow D., Antman E. M., Snapinn S. M. et al. An integrated clinical approach to predicting the benefit of tirofiban in non-ST-segment elevation acute coronary syndromes: Application of the TIMI risk score for UA/NSTEMI in PRISM-PLUS. Eur. Heart J. 2002; 23: 223-229.
  19. Morrow D., Sabatine M., Cannon C. et al. Benefit of tirofiban among patients treated without coronary intervention: Application of the TIMI risk score for unstable angina and non-ST-segment elevation myocardial infarction in PRISM-PLUS, Circulation, 2002; 104 (suppl. II): 782.
  20. Martinez-Rios M. A., Rosas M., Gonzalez H. et al. Comparison of reperfusion regimens with or without tirofiban in ST-elevation acute myocardial infarction. Am. J. Cardiol. 2004; 93: 280-287.
  21. Roffi M., Topol E. Percutaneous coronary intervention in diabetic patients with non-ST-segment elevation acute coronary syndromes. Eur. Heart J. 2004; 25: 190-198.
  22. Roffi M., Chew D. P., Makherjee D. et al. Platelet glycoprotein IIb/IIIa inhibitors reduce mortality in diabetic patients with non-ST-segment-elevation acute coronary syndromes. Circulation 2001; 104: 2767-2771.
  23. Topol E., Moliterno D., Herrmann H. et al. Comparison of two platelet glycoprotein IIb/IIIa inhibitors, tirofiban and abciximab, for the prevention of ischemic events with percutaneous coronary revascularization. N. Engl. J. Med. 2001; 344: 1888-1894.
  24. Kandzari D. E., Califf R. M. TARGET versus GUSTO-IV: appropriate use of glycoprotein IIb/IIIa inhibitors in acute coronary syndromes and percutaneous coronary intervention. Curr. Opin. Cardiol. 2002; 17: 332-339.

Supplementary files

Supplementary Files
Action
1. JATS XML
Download

Copyright (c) 2009 Consilium Medicum

Creative Commons License
This work is licensed under a Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License.
 

Address of the Editorial Office:

  • Novij Zykovskij proezd, 3, 40, Moscow, 125167

Correspondence address:

  • Alabyan Street, 13/1, Moscow, 127055, Russian Federation

Managing Editor:

  • Tel.: +7 (926) 905-41-26
  • E-mail: e.gorbacheva@ter-arkhiv.ru

 

 © 2018-2021 "Consilium Medicum" Publishing house


This website uses cookies

You consent to our cookies if you continue to use our website.

About Cookies